Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

ADR in Journals: Are They Translated into Regulatory Frameworks?

Author(s): Annapurna Kolupoti*, Ananya Chakraborty and K. Shahistha

Volume 17, Issue 1, 2022

Published on: 09 June, 2021

Page: [34 - 39] Pages: 6

DOI: 10.2174/1574886316666210609115148

open access plus

Abstract

Introduction: An adverse drug reaction case report refers to a scientific publication that is written by a health care professional who suspects a casual relationship between a drug and an adverse drug reaction (ADR). ADR case reports help to identify potential risks associated with the use of drug. Most of the case reports do not mention about reporting the ADR to regulatory authorities. With this objective, the aim of this study was to analyze the number of Adverse Drug Reactions (ADR) published as case reports (PubMed indexed journals) from January 2018 to June 2019, and observe if they are translated in regulatory frameworks like Vigibase, and package inserts.

Materials and Methods: 321 ADRs were obtained with the keywords “Adverse Drug Reaction”. Out of those, 158 were independently extracted by two investigators, observed and categorized according to classes of the drugs, geographic location, severity, hospitalization, Completeness of ADR, whether reported to the regulatory authority (Vigibase), or listed in the package insert. Literature review articles were excluded.

Results: Out of the 158 ADRs, antibiotics accounted for 12.65%, CNS drugs and monoclonal antibodies11.39%, anticancer drugs 9.49%, CVS drugs 4.43%, anti-viral 3.79%, others 45.56%, respectively. According to geographic region, 26 ADRs published were from USA, Australia 4, Italy 3, India 17, Turkey 9, Singapore and UK 1, China 20, Denmark and Canada 2, Japan 10, France 9, Austria 1, Korea 5, South America 3, Switzerland 2, respectively. Depending upon the severity, causality assessment was done only for 45 ADRs, and not done for 113 ADRs. 41.13% patients (from 65 case reports) were hospitalized. Among the 158 ADRs, 14 ADRs were not found in Vigibase. 32 ADRs were not mentioned in the Drug package inserts. When categorized according to the completeness of case reports, weight accounted for1.89%, lab values and procedure for diagnosis, 96.8%, risk factors, 95.56%, prior exposure, 88.60%, Post ADR status, 60.12%, start-stop medication, route of administration, first dose, last dose, duration of illness accounted for 100%, respectively.

Conclusion: Depending upon our observation, we have noticed that there is deficiency in reporting of suspected ADRs to regulatory authorities. Reporting can be included as mandatory criteria for ADR case reports. Also, there is an increased need to aware various healthcare workers for reporting ADR.

Keywords: Adverse drug reactions, PubMed data, ethnicity, package insert, completeness of case reports, vigibase.

« Previous Next »
[1]
Kelly WN. The quality of published adverse drug event reports. Ann Pharmacother 2003; 37(12): 1774-8.
[http://dx.doi.org/10.1345/aph.1D202] [PMID: 14632590]
[2]
Kelly WN, Arellano FM, Barnes J, et al. Guidelines for submitting adverse event reports for publication. Pharmacoepidemiol Drug Saf 2007; 16(5): 581-7.
[http://dx.doi.org/10.1002/pds.1399] [PMID: 17471601]
[3]
Oshikoya KA. Approach to publishing adverse event case reports in biomedical journals. Trop J Pharm Res 2011; 10(1): 3-9.
[4]
Lechien JR, Costa de Araujo P, De Marrez LG, Halloy JL, Khalife M, Saussez S. Contact allergy to benzalkonium chloride in patients using a steroid nasal spray: A report of 3 cases. Ear Nose Throat J 2018; 97(1-2): E20-2.
[PMID: 29493726]
[5]
Dogra M, Rohilla V, Dogra M, Singh R. Macular cytomegalovirus retinitis following dexamethasone intravitreal implant combined with phacoemulsification. Indian J Ophthalmol 2018; 66(9): 1361-3.
[http://dx.doi.org/10.4103/ijo.IJO_171_18] [PMID: 30127173]
[6]
Pathania M, Goel B, Dhamija P, Kant R, Dhar M, Mittal S. A rare adverse drug reaction to escitalopram. J Family Med Prim Care 2018; 7(2): 466.
[PMID: 30090797]
[7]
Kang A, Yuen M, Lee DJ. Nivolumab-induced systemic vasculitis. JAAD Case Rep 2018; 4(6): 606-8.
[http://dx.doi.org/10.1016/j.jdcr.2018.03.013] [PMID: 30003129]
[8]
Darwin E, Romanelli P, Lev-Tov H. Ocrelizumab-induced psoriasiform dermatitis in a patient with multiple sclerosis. Dermatol Online J 2018; 24(7): 13030/qt220859qb.
[PMID: 30261571]
[9]
Kataria PS, Kendre PP, Patel AA, Tahiliani N, Bhargav V, Parekh H. Rare occurrence of hand-foot syndrome due to paclitaxel: A rare case report. Indian J Pharmacol 2018; 50(5): 284-6.
[http://dx.doi.org/10.4103/ijp.IJP_547_17] [PMID: 30636833]
[10]
Zheng G, Cao L, Che Z, Mao E, Chen E, He J. Polymyxin B-induced skin hyperpigmentation: A rare case report and literature review. BMC Pharmacol Toxicol 2018; 19(1): 41.
[http://dx.doi.org/10.1186/s40360-018-0226-1] [PMID: 29973293]
[11]
Kim HY, Park SW, Kim JH, Kang JH, Lee WS, Song HN. Romiplostim-related myelofibrosis in refractory primary immune thrombocytopenia: A case report. Medicine (Baltimore) 2019; 98(25): e15882.
[http://dx.doi.org/10.1097/MD.0000000000015882] [PMID: 31232923]
[12]
Yang H, Wang W, Hu X, Zhang X, Liu L. Sirolimus-induced severe small bowel angioedema: A case report. Medicine (Baltimore) 2018; 97(34): e12029.
[http://dx.doi.org/10.1097/MD.0000000000012029] [PMID: 30142853]
[13]
Tadros J, Rahnama-Moghadam S, Small SM, Bacher RS, Jost SA. Erythema annulare centrifugum-type eruption in a patient undergoing cancer vaccine immunotherapy. Dermatol Online J 2018; 24(10): 13030/qt94p9q7wr.
[14]
Leon-Muinos E, Figueroa O, Rosende L, Monteagudo B. Topical tacrolimus-induced lentigines. Ann Pediat 2018; 89(2): 128-9.
[15]
Ruiz-Rivero J, Horcajada-Reales C, Tardío JC, Borbujo-Martínez JM. Multiple spider telangiectasias in a breast cancer patient on T-DM1 treatment. An Bras Dermatol 2018; 93(6): 938-9.
[http://dx.doi.org/10.1590/abd1806-4841.20187968] [PMID: 30484553]
[16]
Del Giorno R, Iodice A, Mangas C, Gabutti L. New-onset cutaneous sarcoidosis under tocilizumab treatment for giant cell arteritis: A quasi-paradoxical adverse drug reaction. Ther Adv Musculoskelet Dis 2019; 11: 1759720X19841796.
[17]
Flora TB, Alves CAXM, Barucci FMP, Mattos CB. Toxic epidermal necrolysis after yellow fever vaccination. An Bras Dermatol 2018; 93(6): 942-3.
[http://dx.doi.org/10.1590/abd1806-4841.20188237] [PMID: 30484555]
[18]
Approved drug products. Available from: www.accessdata.fda.gov
[19]
Geer MI, Koul PA, Tanki SA, Shah MY. Frequency, types, severity, preventability and costs of adverse drug reactions at a tertiary care hospital. J Pharmacol Toxicol Methods 2016; 81: 323-34.
[http://dx.doi.org/10.1016/j.vascn.2016.04.011] [PMID: 27109493]
[20]
Aagaard L, Strandell J, Melskens L, Petersen PS, Holme Hansen E. Global patterns of adverse drug reactions over a decade: Analyses of spontaneous reports to VigiBase™. Drug Saf 2012; 35(12): 1171-82.
[http://dx.doi.org/10.1007/BF03262002] [PMID: 23072620]
[21]
Murayama H, Sakuma M, Takahashi Y, Morimoto T. Improving the assessment of adverse drug reactions using the Naranjo Algorithm in daily practice: The Japan Adverse Drug Events Study. Pharmacol Res Perspect 2018; 6(1): e00373.
[http://dx.doi.org/10.1002/prp2.373] [PMID: 29417762]
[22]
Available from: https://www.fda.gov/safety/reporting-serious-problems-fda/what-serious-adverse-event
[23]
Angamo MT, Curtain CM, Chalmers L, Yilma D, Bereznicki L. Predictors of adverse drug reaction-related hospitalisation in Southwest Ethiopia: A prospective cross-sectional study. PLoS One 2017; 12(10): e0186631.
[http://dx.doi.org/10.1371/journal.pone.0186631] [PMID: 29036230]
[24]
Ognibene S, Vazzana N, Giumelli C, Savoldi L, Braglia L, Chesi G. Hospitalisation and morbidity due to adverse drug reactions in elderly patients: A single-centre study. Intern Med J 2018; 48(10): 1192-7.
[http://dx.doi.org/10.1111/imj.13961] [PMID: 29740921]
[25]
van Hunsel F, van de Koppel S, Skalli S, et al. Analysis of hepatobiliary disorder reports associated with the use of herbal medicines in the global suspected ADR database vigibase. Front Pharmacol 2019; 10: 1326.
[http://dx.doi.org/10.3389/fphar.2019.01326] [PMID: 31780942]
[26]
Mahajan MM, Thatte UM, Gogtay NJ, Deshpande S. An analysis of completeness and quality of adverse drug reaction reports at an adverse drug reaction monitoring centre in Western India. Perspect Clin Res 2018; 9(3): 123-6.
[http://dx.doi.org/10.4103/picr.PICR_105_17] [PMID: 30090710]

Rights & Permissions Print Cite
Article Metrics
27
1
© 2024 Bentham Science Publishers | Privacy Policy